🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 89532M101
- Market Cap
- Small Cap
- IPO
- 5/7/2019 · $10.00/share
Business: Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis and levodopa-induced dyskinesia in patients with Parkinson’s disease. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems.
Company Contact
- CEO
- Jennifer Good
- CFO
- Lisa Delfini
- Headquarters
- 195 Church Street, 14th Floor, New Haven, CT 06510
- Phone
- 203-304-2499
- Investor Relations
- Katie McManus · 203-903-9627 · kmcmanus@trevitherapeutics.com